Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9701, pp. 1617 - 1625
Summary Background Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are...
Internal Medicine | SOLID-ORGAN TRANSPLANTATION | LYMPHOMA RISK | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CROHNS-DISEASE | INCREASED RISK | AZATHIOPRINE | METHOTREXATE | INFLIXIMAB | CANCER | Crohn Disease - epidemiology | Multivariate Analysis | Age Distribution | Prospective Studies | Humans | Middle Aged | Lymphoproliferative Disorders - chemically induced | Male | Colitis, Ulcerative - epidemiology | Incidence | Time Factors | Adult | Female | Purines - adverse effects | Colitis, Ulcerative - drug therapy | Drug Therapy, Combination | France - epidemiology | Risk Factors | Proportional Hazards Models | Lymphoproliferative Disorders - epidemiology | Crohn Disease - drug therapy | Sex Distribution | Immunosuppressive Agents - adverse effects | Aged | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Complications and side effects | Inflammatory bowel diseases | Lymphoproliferative disorders | Gastrointestinal agents | Patient outcomes | Dosage and administration | Diagnosis | Drug therapy | Risk factors | Inflammatory bowel disease | Bowel disease | Gastroenterology | Cancer | Index Medicus | Abridged Index Medicus
Internal Medicine | SOLID-ORGAN TRANSPLANTATION | LYMPHOMA RISK | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CROHNS-DISEASE | INCREASED RISK | AZATHIOPRINE | METHOTREXATE | INFLIXIMAB | CANCER | Crohn Disease - epidemiology | Multivariate Analysis | Age Distribution | Prospective Studies | Humans | Middle Aged | Lymphoproliferative Disorders - chemically induced | Male | Colitis, Ulcerative - epidemiology | Incidence | Time Factors | Adult | Female | Purines - adverse effects | Colitis, Ulcerative - drug therapy | Drug Therapy, Combination | France - epidemiology | Risk Factors | Proportional Hazards Models | Lymphoproliferative Disorders - epidemiology | Crohn Disease - drug therapy | Sex Distribution | Immunosuppressive Agents - adverse effects | Aged | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Complications and side effects | Inflammatory bowel diseases | Lymphoproliferative disorders | Gastrointestinal agents | Patient outcomes | Dosage and administration | Diagnosis | Drug therapy | Risk factors | Inflammatory bowel disease | Bowel disease | Gastroenterology | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 931 - 942
Summary Background More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based...
Hematology, Oncology and Palliative Medicine | CANCER SURVIVAL | SUBTYPE | B-CELL LYMPHOMA | THERAPY | ONCOLOGY | LONG-TERM SURVIVAL | IMATINIB | CHOP | LEUKEMIA | CHEMOTHERAPY PLUS RITUXIMAB | Hematologic Neoplasms - therapy | Severity of Illness Index | Hematologic Neoplasms - diagnosis | Confidence Intervals | Risk Assessment | Europe | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Combined Modality Therapy | Cause of Death | Young Adult | Disease-Free Survival | Adolescent | Survival Analysis | Adult | Female | Registries | Aged | Retrospective Studies | Cohort Studies | Public health | Cancer
Hematology, Oncology and Palliative Medicine | CANCER SURVIVAL | SUBTYPE | B-CELL LYMPHOMA | THERAPY | ONCOLOGY | LONG-TERM SURVIVAL | IMATINIB | CHOP | LEUKEMIA | CHEMOTHERAPY PLUS RITUXIMAB | Hematologic Neoplasms - therapy | Severity of Illness Index | Hematologic Neoplasms - diagnosis | Confidence Intervals | Risk Assessment | Europe | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Combined Modality Therapy | Cause of Death | Young Adult | Disease-Free Survival | Adolescent | Survival Analysis | Adult | Female | Registries | Aged | Retrospective Studies | Cohort Studies | Public health | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1022 - 1039
Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined...
CANCER SURVIVAL | HEAD | IMPACT | QUALITY | ONCOLOGY | EUROCARE-5 | NECK-CANCER | EPIDEMIOLOGY | Rare Diseases - mortality | Humans | Europe - epidemiology | Hospitalization - statistics & numerical data | Neoplasms - mortality | Rare Diseases - epidemiology | Male | Survival Rate | Cancer Care Facilities | Incidence | Neoplasms - therapy | Rare Diseases - therapy | Delivery of Health Care | Female | Registries | Neoplasms - epidemiology | Life Sciences
CANCER SURVIVAL | HEAD | IMPACT | QUALITY | ONCOLOGY | EUROCARE-5 | NECK-CANCER | EPIDEMIOLOGY | Rare Diseases - mortality | Humans | Europe - epidemiology | Hospitalization - statistics & numerical data | Neoplasms - mortality | Rare Diseases - epidemiology | Male | Survival Rate | Cancer Care Facilities | Incidence | Neoplasms - therapy | Rare Diseases - therapy | Delivery of Health Care | Female | Registries | Neoplasms - epidemiology | Life Sciences
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 09/2016, Volume 2016, Issue 485, p. 25
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 04/2019, Volume 2019, Issue 511, pp. 27 - 27
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 01/2019, Volume 2019, Issue 508, pp. 1 - 1
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 11/2012, Volume 18, Issue 11, pp. 2063 - 2071
Background: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative...
CESAME study | primary intestinal lymphomas | thiopurines | inflammatory bowel disease | POPULATION | CROHNS-DISEASE | GASTROINTESTINAL-TRACT | ULCERATIVE-COLITIS | SURGICAL-TREATMENT | FEATURES | INCREASED RISK | NEOPLASIA | NON-HODGKINS-LYMPHOMA | GASTROENTEROLOGY & HEPATOLOGY | EPSTEIN-BARR-VIRUS | Colitis, Ulcerative - complications | Azathioprine - therapeutic use | France - epidemiology | Prospective Studies | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Treatment Outcome | Case-Control Studies | Crohn Disease - complications | Incidence | Lymphoproliferative Disorders - epidemiology | Young Adult | Mercaptopurine - therapeutic use | Aged, 80 and over | Adult | Female | Lymphoproliferative Disorders - drug therapy | Aged | Child | Lymphoproliferative Disorders - etiology | Care and treatment | Gastrointestinal diseases | Organic chemistry | Chemical Sciences
CESAME study | primary intestinal lymphomas | thiopurines | inflammatory bowel disease | POPULATION | CROHNS-DISEASE | GASTROINTESTINAL-TRACT | ULCERATIVE-COLITIS | SURGICAL-TREATMENT | FEATURES | INCREASED RISK | NEOPLASIA | NON-HODGKINS-LYMPHOMA | GASTROENTEROLOGY & HEPATOLOGY | EPSTEIN-BARR-VIRUS | Colitis, Ulcerative - complications | Azathioprine - therapeutic use | France - epidemiology | Prospective Studies | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Treatment Outcome | Case-Control Studies | Crohn Disease - complications | Incidence | Lymphoproliferative Disorders - epidemiology | Young Adult | Mercaptopurine - therapeutic use | Aged, 80 and over | Adult | Female | Lymphoproliferative Disorders - drug therapy | Aged | Child | Lymphoproliferative Disorders - etiology | Care and treatment | Gastrointestinal diseases | Organic chemistry | Chemical Sciences
Journal Article
Nature Communications [E], ISSN 2041-1723, 2016, Volume 7, Issue 1, p. 10933
Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy with strong heritability. To further understand the genetic susceptibility for CLL and...
Membrane Proteins | Adaptor Proteins, Signal Transducing | Genetic Predisposition to Disease | Genome-Wide Association Study | Apoptosis Regulatory Proteins | Humans | Serpins | European Continental Ancestry Group | Polymorphism, Single Nucleotide | Proto-Oncogene Proteins | T-Box Domain Proteins | Leukemia, Lymphocytic, Chronic, B-Cell | VARIANTS | BANK1 | MULTIDISCIPLINARY SCIENCES | SUSCEPTIBILITY LOCI | RISK | CLASSIFICATION | FAS GENE-MUTATIONS | FOLLICULAR LYMPHOMA | PRIORITIZATION | COMMON VARIATION | IDENTIFICATION | European Continental Ancestry Group - genetics | Serpins - genetics | Membrane Proteins - genetics | Proto-Oncogene Proteins - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | T-Box Domain Proteins - genetics | Bcl-2-Like Protein 11 | Adaptor Proteins, Signal Transducing - genetics | Apoptosis Regulatory Proteins - genetics | Chronic lymphatic leukemia | Leukemia | Agent orange | Genomes | Single-nucleotide polymorphism | Malignancy | Lymphatic leukemia | Chromosome 4 | Chromosome 3 | Loci | Chromosome 2 | Heritability | Apoptosis | Samfunnsmedisin, sosialmedisin: 801 | Community medicine, Social medicine: 801 | VDP | Helsefag: 800 | Health sciences: 800 | Medisinske Fag: 700 | Medical disciplines: 700 | Life Sciences | Hematology | Human health and pathology | Medical and Health Sciences | Medicin och hälsovetenskap
Membrane Proteins | Adaptor Proteins, Signal Transducing | Genetic Predisposition to Disease | Genome-Wide Association Study | Apoptosis Regulatory Proteins | Humans | Serpins | European Continental Ancestry Group | Polymorphism, Single Nucleotide | Proto-Oncogene Proteins | T-Box Domain Proteins | Leukemia, Lymphocytic, Chronic, B-Cell | VARIANTS | BANK1 | MULTIDISCIPLINARY SCIENCES | SUSCEPTIBILITY LOCI | RISK | CLASSIFICATION | FAS GENE-MUTATIONS | FOLLICULAR LYMPHOMA | PRIORITIZATION | COMMON VARIATION | IDENTIFICATION | European Continental Ancestry Group - genetics | Serpins - genetics | Membrane Proteins - genetics | Proto-Oncogene Proteins - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | T-Box Domain Proteins - genetics | Bcl-2-Like Protein 11 | Adaptor Proteins, Signal Transducing - genetics | Apoptosis Regulatory Proteins - genetics | Chronic lymphatic leukemia | Leukemia | Agent orange | Genomes | Single-nucleotide polymorphism | Malignancy | Lymphatic leukemia | Chromosome 4 | Chromosome 3 | Loci | Chromosome 2 | Heritability | Apoptosis | Samfunnsmedisin, sosialmedisin: 801 | Community medicine, Social medicine: 801 | VDP | Helsefag: 800 | Health sciences: 800 | Medisinske Fag: 700 | Medical disciplines: 700 | Life Sciences | Hematology | Human health and pathology | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 04/2019, Volume 2019, Issue 511, p. 28
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 20, pp. e90 - e98
After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working...
FOLLICULAR LYMPHOMAS | PROGNOSTIC INDEX | UNITED-STATES | B-CELL LYMPHOMA | CONSORTIUM INTERLYMPH | GENE-EXPRESSION | UNDETERMINED SIGNIFICANCE | NON-HODGKIN-LYMPHOMA | POOLED ANALYSIS | MONOCLONAL GAMMOPATHY | HEMATOLOGY | Lymphoma - epidemiology | Epidemiologic Studies | Lymphoma - classification | Societies, Medical | World Health Organization | Humans | Lymphoma - pathology | Lymphoid Neoplasia
FOLLICULAR LYMPHOMAS | PROGNOSTIC INDEX | UNITED-STATES | B-CELL LYMPHOMA | CONSORTIUM INTERLYMPH | GENE-EXPRESSION | UNDETERMINED SIGNIFICANCE | NON-HODGKIN-LYMPHOMA | POOLED ANALYSIS | MONOCLONAL GAMMOPATHY | HEMATOLOGY | Lymphoma - epidemiology | Epidemiologic Studies | Lymphoma - classification | Societies, Medical | World Health Organization | Humans | Lymphoma - pathology | Lymphoid Neoplasia
Journal Article